End Stage Renal Disease Treatment Market Analysis 2026

Global End Stage Renal Disease Treatment Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

End Stage Renal Disease Treatment Market Report Description

We have various report editions of End Stage Renal Disease Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The April 2025 “Liberation Day Tariffs” (10–46%) have disrupted global pharmaceutical trade, raising costs for APIs, packaging, and machinery from China and India. Generic drug makers, biopharma, vaccines, and CMOs face higher expenses, supply chain delays, and regulatory hurdles, while EU retaliation has further strained U.S. exports. Clinical trials are also delayed due to tariffs on drugs and kits. In this landscape, market research is vital, providing real-time data on pricing, suppliers, and tariff impacts to help companies optimize supply chains, find alternative hubs, and maintain competitiveness.

End Stage Renal Disease Treatment Market Insights Video

Competitive Landscape of the End-Stage Renal Disease Treatment Market

The End Stage Renal Disease (ESRD) treatment market is highly competitive, with key players leading through extensive dialysis networks and innovative treatment options. Companies focus on expanding home-based dialysis and advanced hemodialysis technology to meet rising demand. Partnerships with healthcare providers and advancements in portable devices enhance market position, while newer entrants target emerging regions with cost-effective solutions. Increasing investment in kidney care infrastructure and transplant innovation further intensifies competition.

In April 2022, Ardelyx announced the FDA approval of Tenapanor for reducing serum phosphorus in adults with chronic kidney disease on dialysis. (Source: https://ir.ardelyx.com/news-releases/news-release-details/fda-approves-xphozahr-tenapanor-first-class-phosphate-absorption) In January 2023, The US Food and Drug Administration (FDA) approved a supplement new drug application for Jardiance tablets, which is being researched as potential treatment to lower the risk of kidney disease progression and the cardiovascular deaths in adults with chronic kidney disease. (Source: https://investor.lilly.com/news-releases/news-release-details/us-fda-accepts-supplemental-new-drug-application-jardiancer-0)

Top Companies Market Share in End Stage Renal Disease Treatment Industry: (In no particular order of Rank)

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive)

Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the End-Stage Renal Disease Treatment Market

Which Region Dominates the End Stage Renal Disease Treatment Market in 2024?

According to Cognitive Market Research, North America currently dominates the End Stage Renal Disease Treatments market, and the region is expected to have significant growth during the projected period. This is due to a high prevalence of kidney-related diseases, advanced healthcare infrastructure, and significant government support for dialysis and transplant services.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Improved healthcare infrastructure, increased adoption of dialysis treatments, and growing awareness of kidney disease drive significant market expansion across various countries.

The current report Scope analyzes End Stage Renal Disease Treatment Market on 6 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (East Africa, West Africa, North Africa, South Africa)

The above graph is for illustrative purposes only.

North America End Stage Renal Disease Treatment Market Analysis

According to Cognitive Market Research, the global End Stage Renal Disease Treatment market size was estimated at USD 115215.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 46086.20 million in 2024 and will rise at the compound annual growth rate (CAGR) of 12.4% from the year 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the End Stage Renal Disease Treatment market with a market size of USD 36362.01 million in 2024 and is foreseen to rise at the CAGR of 12.2% during the forecast years due to the advancements in dialysis technology and home dialysis solutions.
• The Canada End Stage Renal Disease Treatment market had a market share of USD 5530.34 million in 2024 and is foreseen to rise at the CAGR of 13.2% during the forecast years due to the increasing healthcare investments and government support programs.
• The Mexico End Stage Renal Disease Treatment market is foreseen to witness growth at a CAGR of 12.9% during the forecast period, with a market size of USD 4193.84 million in 2024.

Europe End Stage Renal Disease Treatment Market Analysis

According to Cognitive Market Research, the global End Stage Renal Disease Treatment market size was estimated at USD 115215.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 34564.65 million in 2024 and will rise at the compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.

• The United Kingdom End Stage Renal Disease Treatment market had a market share of USD 5806.86 million in 2024 and is projected to rise at a CAGR of 13.5% during the forecast years. In the UK, End Stage Renal Disease Treatment sales witness an upswing due to the advancements in dialysis technologies and treatment modalities.
• The France End Stage Renal Disease Treatment market is foreseen to witness growth at the CAGR of 11.9% during the forecast years, with a market size of USD 3179.95 million in 2024.
• According to Cognitive Market Research, the German End Stage Renal Disease Treatment market size was valued at USD 6843.80 million in 2024 and is foreseen to rise at the CAGR of 12.9% during the forecast years. In Germany, End Stage Renal Disease Treatment surged due to government initiatives and reimbursement policies supporting ESRD care.
• The Italy End Stage Renal Disease Treatment market is foreseen to witness growth at the CAGR of 12.1% during the forecast period, with a market size of USD 2972.56 million in 2024.
• The Russia End Stage Renal Disease Treatment market is foreseen to witness growth at the CAGR of 11.7% during the forecast years, with a market size of USD 5357.52 million in 2024.
• The Spain End Stage Renal Disease Treatment market is foreseen to witness growth at the CAGR of 11.8% during the forecast period with a market size of USD 2834.30 million in 2024
• The Luxembourg End Stage Renal Disease Treatment market is foreseen to witness growth at the CAGR of 12.8% during the forecast years, with a market size of USD 1071.50 million in 2024.
• The Portugal End Stage Renal Disease Treatment market is foreseen to witness growth at a CAGR of 12.5% during the forecast period, with a market size of USD 725.86 million in 2024.
• The Greece End Stage Renal Disease Treatment market is foreseen to witness growth at a CAGR of 13.0% during the forecast period, with a market size of USD 414.78 million in 2024.
• The Rest of Europe's End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 11.4% during the forecast period, with a market size of USD 5357.52 million in 2024.

Asia Pacific End Stage Renal Disease Treatment Market Analysis

According to Cognitive Market Research, the global End Stage Renal Disease Treatment market size was estimated at USD 115215.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 26499.57 million in 2024 and will rise at the compound annual growth rate (CAGR) of 16.2% from 2024 to 2031.

• According to Cognitive Market Research, the China End Stage Renal Disease Treatment market size was valued at USD 11924.80 million in 2024 and is foreseen to rise at a CAGR of 15.7% during the forecast period. End Stage Renal Disease Treatment surged in China due to the improved healthcare infrastructure and access.
• The Japan End Stage Renal Disease Treatment market is foreseen to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 3656.94 million in 2024.
• The India End Stage Renal Disease Treatment market had a market share of USD 3179.95 million in 2024 and is foreseen to rise at the CAGR of 18.0% during the forecast period due to the government initiatives and insurance coverage expansion .
• The South Korean End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 15.3% during the forecast period, with a market size of USD 2649.96 million in 2024.
• The Australian End Stage Renal Disease Treatment market is foreseen to witness growth at a CAGR of 15.9% during the forecast period, with a market size of USD 1377.98 million in 2024.
• The South East Asia End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 17.2% during the forecast period, with a market size of USD 1828.47 million in 2024.
• The Rest of Asia Pacific End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 16.0% during the forecast period, with a market size of USD 1881.47 million in 2024.

South America End Stage Renal Disease Treatment Market Analysis

According to Cognitive Market Research, the global End Stage Renal Disease Treatment market size was estimated at USD 115215.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 5760.78 million in 2024 and will rise at the compound annual growth rate (CAGR) of 13.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil End Stage Renal Disease Treatment market size was valued at USD 2465.61 million in 2024 and is foreseen to rise at the CAGR of 14.2% during the forecast period. End Stage Renal Disease Treatments flourished in Brazil due to the Expanding healthcare infrastructure and investment in dialysis facilities.
• Argentina's End Stage Renal Disease Treatment market had a market share of USD 967.81 million in 2024 and is foreseen to rise at the CAGR of 14.5% during the forecast years due to the increased government initiatives and subsidies for kidney disease treatments.
• Colombia's End Stage Renal Disease Treatment market is foreseen to witness growth at a CAGR of 13.4% during the forecast period, with a market size of USD 512.71 million in 2024.
• Peru End Stage Renal Disease Treatment market is foreseen to witness growth at a CAGR of 13.8% during the forecast period, with a market size of USD 472.38 million in 2024.
• Chile's End Stage Renal Disease Treatment market is foreseen to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 414.78 million in 2024.
• The Rest of Latin America's End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 927.48 million in 2024.

Middle East End Stage Renal Disease Treatment Market Analysis

According to Cognitive Market Research, the global End Stage Renal Disease Treatment market size was estimated at USD 115215.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 2304.31 million in 2024 and will rise at the compound annual growth rate (CAGR) of 13.9% from the year 2024 to 2031..

• The GCC Countries End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 986.24 million in 2024. End Stage Renal Disease Treatment sales flourish due to the surging government investments in the healthcare infrastructure.
• The Egypt End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 14.2% during the forecast period, with a market size of USD 241.95 million in 2024.
• The South African End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 14.9% during the forecast period, with a market size of USD 364.08 million in 2024. End Stage Renal Disease Treatment sales flourished in South Africa due to the growing awareness and access to advanced dialysis treatments.
• The Turkey End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 13.4% during the forecast period, with a market size of USD 198.17 million in 2024.
• The Nigeria End Stage Renal Disease Treatment market is projected to witness growth at a CAGR of 13.0% during the forecast period, with a market size of USD 241.95 million in 2024.
• The Rest of the MEA End Stage Renal Disease Treatment market is foreseen to witness growth at the CAGR of 12.9% during the forecast years, with a market size of USD 271.91 million in 2024.

Author's Conclusion

Author's Detail

Supriya Yadav

Research Analyst

LinkedIn | Profile | Book Appointment

Supriya Yadav is a dedicated market research professional with expertise in the aerospace and defence industry. At Cognitive Market Research, she focuses on delivering strategic insights into aviation advancements, defence technologies, and global security trends shaping the future of the sector.

Her research covers areas such as military modernization, commercial aviation growth, space exploration, and defence procurement strategies. With a strong analytical mindset and attention to technological evolution, Supriya provides data-driven intelligence that supports innovation, strategic planning, and informed decision-making within the aerospace and defence domain.